| 尼妥珠单抗联合化疗药物对人结肠癌细胞株LoVo的实验研究 |
| |
| 引用本文： | 李小燕,曹梦苒,吕成伟,郑大勇,苏宁,罗荣城. 尼妥珠单抗联合化疗药物对人结肠癌细胞株LoVo的实验研究[J]. 热带医学杂志, 2009, 9(5): 483-486 |
| |
| 作者姓名： | 李小燕 曹梦苒 吕成伟 郑大勇 苏宁 罗荣城 |
| |
| 作者单位： | 南方医科大学南方医院肿瘤中心,广州,510515;南方医科大学南方医院肿瘤中心,广州,510515;南方医科大学南方医院肿瘤中心,广州,510515;南方医科大学南方医院肿瘤中心,广州,510515;南方医科大学南方医院肿瘤中心,广州,510515;南方医科大学南方医院肿瘤中心,广州,510515 |
| |
| 基金项目： | 广东省自然科学基金(No.30801308) |
| |
| 摘 要： | 目的探讨表皮生长因子受体(EGFR)的单克隆抗体尼妥珠单(nimotuzumab,h-R3)与化疗药物联合对结肠癌细胞株LoVo的作用,初步探讨其可能的作用机制。方法采用MTT法测定不同药物单药、两药联合分别对结肠癌细胞株LoVo的IC50值;计算不同药物联合的q值,以确定药物联合的作用;流式细胞仪检测不同药物单药或者联合对细胞周期分布及凋亡比例的影响。结果联合h-R3能显著提高伊立替康对LoVo细胞的细胞抑制率,诱导更多肿瘤细胞发生凋亡以及产生G0/G1期、G2/M期阻滞,与5-氟尿嘧啶联合具有类似的作用,但较伊立替康不明显,而与奥沙利铂联合无明显增效作用。结论h-R3通过协同或相加作用提高伊立替康、氟尿嘧啶的细胞杀伤作用,其机制与促进细胞凋亡和影响细胞周期分布有关,奥沙利铂联合对LoVo细胞无明显增效作用。为进一步的体内及体外实验提供了一定的指导作用。
|
| 关 键 词： | 表皮生长因子受体 尼妥珠单抗 化学治疗 结直肠癌 |
An Experimental Study on Effect of Chemotherapeutic Agents Combined with Nimotuzumab on Human Colon Cell Line LoVo |
| |
| LI Xiao-yan,CAO Meng-ran,LV Cheng-wei,ZHENG Da-yong,SU Ning,LUO Rong-cheng. An Experimental Study on Effect of Chemotherapeutic Agents Combined with Nimotuzumab on Human Colon Cell Line LoVo[J]. Journal Of Tropical Medicine, 2009, 9(5): 483-486 |
| |
| Authors: | LI Xiao-yan CAO Meng-ran LV Cheng-wei ZHENG Da-yong SU Ning LUO Rong-cheng |
| |
| Affiliation: | Center of Oncology;Nanfang Hospital;Southern Medical University;Guangzhou 510515;China |
| |
| Abstract: | Objective To investigate the effect and the possible mechanisms of cytotoxic agents combined with nimotuzumab in human colon LoVo cell line.Methods Inhibition of cell proliferation was evaluated by MTT assay.The combination effect was determined by q value.Cell cycle and apoptosis were analyzed by FACS.Results Combined treatment with h-R3 and nimotuzumab could not only enhance the growth inhibition but also increase apoptosis and cell cycle(G0 /G1 and G2 /M) arrest of LoVo cells.The effect was less apparent... |
| |
| Keywords: | EGFR nimotuzumab chemotherapy colorectal cancer |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
